Multi-stage enrichment and basket trial designs with population selection
- PMID: 31621949
- DOI: 10.1002/sim.8371
Multi-stage enrichment and basket trial designs with population selection
Abstract
As biomarker information from early-phase trials can be unreliable due to high variability, it is logical to take a prospective two-stage approach when designing a late-phase confirmatory trial, ie, refining the target population at the first stage and performing the hypothesis testing at the second stage. The use of a reliable intermediate endpoint at the first stage can further improve the trial efficiency from both time and cost perspectives. Nevertheless, there are needs for expanding such two-stage confirmatory designs to more stages for monitoring efficacy on the refined population. There is limited literature on this matter, particularly for two popular designs with population selection midway, ie, the biomarker enrichment design and the basket design. In this manuscript, we focus on these two popular designs and discuss how to implement the interim efficacy analyses after population refinement while controlling type I error. Power and stopping probability are also explored for the two designs.
Keywords: O'Brien-Fleming boundary; ascending design; basket design; biomarker adaptive enrichment; population selection.
© 2019 John Wiley & Sons, Ltd.
Similar articles
-
Two-stage enrichment clinical trial design with adjustment for misclassification in predictive biomarkers.Stat Med. 2019 Dec 20;38(29):5445-5469. doi: 10.1002/sim.8370. Epub 2019 Oct 17. Stat Med. 2019. PMID: 31621944 Free PMC article.
-
Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.Stat Med. 2017 May 30;36(12):1843-1861. doi: 10.1002/sim.7272. Epub 2017 Mar 17. Stat Med. 2017. PMID: 28303586
-
Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.Stat Med. 2014 Nov 20;33(26):4515-31. doi: 10.1002/sim.6272. Epub 2014 Jul 30. Stat Med. 2014. PMID: 25130879
-
Adaptive designs in clinical trials: a systematic review-part I.BMC Med Res Methodol. 2024 Oct 4;24(1):229. doi: 10.1186/s12874-024-02272-9. BMC Med Res Methodol. 2024. PMID: 39367313 Free PMC article.
-
A Systematic Review of Adaptive Seamless Clinical Trials for Late-Phase Oncology Development.Ther Innov Regul Sci. 2024 Sep;58(5):917-929. doi: 10.1007/s43441-024-00670-1. Epub 2024 Jun 11. Ther Innov Regul Sci. 2024. PMID: 38861131
Cited by
-
Basket trials in oncology: a systematic review of practices and methods, comparative analysis of innovative methods, and an appraisal of a missed opportunity.Front Oncol. 2023 Nov 14;13:1266286. doi: 10.3389/fonc.2023.1266286. eCollection 2023. Front Oncol. 2023. PMID: 38033501 Free PMC article.
References
REFERENCES
-
- Stallard N, Todd S. Seamless phase II/III design. Stat Methods Med Res. 2010;20(6):623-634. https://doi.org/10.1177/0962280210379035
-
- Magnusson BP, Turnbull BW. Group sequential enrichment design incorporating subgroup selection. Statist Med. 2013;32(16):2695-2714. https://doi.org/10.1002/sim.5738
-
- Mehta C, Schafer H, Daniel H, Irle S. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints. Statist Med. 2014;33(26):4515-4531. https://doi.org/10.1002/sim.6272
-
- Jenkins M, Stone A, Jennison C. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharm Stat. 2011;10:347-356. https://doi.org/10.1002/pst.472
-
- Todd S, Stallard N. A new clinical trial design combining phases 2 and 3: sequential designs with treatment selection and a change of endpoint. Drug Inf J. 2005;39:109-118.
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials